

          1. Participating in any other clinical trial of an experimental agent for COVID-19

          2. On hydroxychloroquine at any time during hospitalization, or within 180 days of
             hospitalization for COVID-19 regardless of indication

          3. History of G6PD deficiency, cirrhosis, long QT syndrome or porphyria of any
             classification

          4. Most recent ECG prior to time of screening with QTc of >=500 msec

          5. Known hypersensitivity to hydroxychloroquine or 4-aminoquinoline derivatives

          6. Death anticipated within 48 hours of enrollment

          7. Inability to obtain informed consent from the patient or designated medical decision
             maker
      